LBA:01:17 ASSESSLE: a novel disease activity tool for the assessment of systemic lupus erythematosus

ObjectivesThe 2023 EULAR and 2025 ACR SLE recommendations endorse a treat-to-target (T2T) strategy aiming for sustained remission or low disease activity (LDA), with prednisone (PDN) <=5 mg/day and withdrawal when possible.However, real-world data on T2T attainability, particularly GC-free remission, remain limited.It is unclear whether these targets are aspirational or achievable in routine care.Our goal was to assess the proportion of SLE patients attaining the recommend-